ASCO GU 2019 Penile, Urethral, Testicular, and Adrenal Cancers

Viewing 1-17 of 17 articles

ASCO GU 2019: Fierce-21: Phase II Study of Vofatamab, a Selective Inhibitor of FGFR3, as Salvage Therapy in Metastatic Urothelial Carcinoma

ASCO GU 2019: Health-Related Quality of Life Reporting in Phase III Randomized Controlled Trials of Metastatic Prostate Adenocarcinoma and Urothelial Carcinoma

ASCO GU 2019: Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

ASCO GU 2019: Phase II Study of Ribociclib in Men with Unresectable, Incurable Teratoma with Recent Progression

ASCO GU 2019: Malignant Pheochromocytoma: Comprehensive Genomic Profiling Study

ASCO GU 2019: Accelerated versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

ASCO GU 2019: The PRIMETEST Trial: Interim Analysis of a Phase II Trial for Primary Retroperitoneal Lymph Node Dissection (RPLND) in Stage II A/B Seminoma Patients without Adjuvant Treatment

ASCO GU 2019: Patients with Previously Treated Metastatic Urothelial Cancer Treated with Sacituzumab Govitecan (IMMU-132)

ASCO GU 2019: Metastatic Seminomas Show Expression of Immune Related Pathways

ASCO GU 2019: Penile Squamous Cell Carcinoma is Genomically Similar to Other HPV-Driven Tumors

ASCO GU 2019: Point-Counterpoint: Subgroup Analyses Can Be Used to Change Clinical Practice Guidelines

ASCO GU 2019: Penile Carcinoma Regional Lymph Node Involvement: Radiation Versus Surgery – Surgeon Perspective

ASCO GU 2019: Practice Makes Perfect: Should All Testicular Cancer Cases Be Discussed with High-Volume Centers?

ASCO GU 2019: Penile Carcinoma Regional Lymph Node Involvement: Radiation Versus Surgery – Radiation Oncology Perspective

ASCO GU 2019: MicroRNA 371 As a Biomarker: Is It a Breakthrough?

ASCO GU 2019: Whole Genome and Transcriptome Analysis of Metastatic Adrenocortical Carcinoma

ASCO GU 2019: Outcome of Men with Relapses after Adjuvant BEP for Clinical Stage I Nonseminoma

email news signup